Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922659 | 0.88 | NPC1 (0.53) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL2747349 | 0.84 | NPC1 (0.56) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL2747345 | 0.84 | NPC1 (0.56) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL3930204 | 0.83 | NPC1 (0.51) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL24609344 | 0.83 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL2543698 | 0.83 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL17330350 | 0.83 | PNMT (0.56) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL951923 | 0.83 | NPC1 (0.55) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL5262284 | 0.83 | SIGMAR1 (0.56) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL27220740 | 0.83 | SIGMAR1 (0.56) | NPC1RAB9ALMNATAAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | NPC1 53/4885RAB9A 2682/4885LMNA 2274/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | NPC1 48/4885RAB9A 1216/4885LMNA 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.